We are developing a Siglec agonist fusion protein and an antagonist anti-Siglec antibody to reduce immune-related adverse events (irAEs) and fight solid tumors.
The binding of Siglecs to sialic acids plays a crucial role in cell-cell interaction and communication, particularly in the immune system.1 We are developing Siglec agonist fusion protein and an antagonist anti-Siglec antibody to respectfully reduce irAE and fight solid tumors.
Some cancers exploit Siglec-10 signaling to avoid being recognized and attacked by the immune system. Targeting this protein in solid tumors may enable the patient's immune system to better fight cancer.2 Our potential first-in-class anti-Siglec-10 mAb has shown antitumor activity in syngeneic xenograft models.
- ONC-841 effectively targets Siglec-10 on microglia in brain
- Preclinical studies reveal its in vivo activity in ameliorating Ab and pTau pathology in mice
- Preclinical studies provide rationale for testing the drug in Alzeimer's and possibly other neuro-degenerative diseases
- Clinical study on early-stage Alzheimer's disease will be launched in US in 1H 2026
